{"id":1491,"date":"2004-02-01T12:01:00","date_gmt":"2004-02-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/angiotensin-ii-rezeptor-blocker-und-oder-ace-hemmer-bei-postinfarzieller-herzinsuffizienz-die-valiant-studie"},"modified":"2004-02-01T12:01:00","modified_gmt":"2004-02-01T11:01:00","slug":"angiotensin-ii-rezeptor-blocker-und-oder-ace-hemmer-bei-postinfarzieller-herzinsuffizienz-die-valiant-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/angiotensin-ii-rezeptor-blocker-und-oder-ace-hemmer-bei-postinfarzieller-herzinsuffizienz-die-valiant-studie","title":{"rendered":"Angiotensin-II-Rezeptor-Blocker und\/oder ACE-Hemmer bei postinfarzieller Herzinsuffizienz. Die VALIANT-Studie"},"content":{"rendered":"<p>Im Dezember hatten wir \u00fcber die im Lancet breit ausgewalzten Ergebnisse der CHARM-Studien berichtet (1). Die Ergebnisse vermitteln den Eindruck, da\u00df die zus\u00e4tzliche Gabe von Candesartan (Atacand\u00ae, Blopress\u00ae) zur Standardtherapie eines Patienten mit Herzinsuffizienz effektiv sein k\u00f6nnte. Die Standardtherapie schlo\u00df ACE-Hemmer, Beta-Blocker, Diuretikum, Digitalis und Spironolacton ein in Dosierungen, die dem behandelnden Arzt \u00fcberlassen waren. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im Dezember hatten wir \u00fcber die im Lancet breit ausgewalzten Ergebnisse der CHARM-Studien berichtet (1). Die Ergebnisse vermitteln den Eindruck, da\u00df die zus\u00e4tzliche Gabe von Candesartan (Atacand\u00ae, Blopress\u00ae) zur Standardtherapie eines Patienten mit Herzinsuffizienz effektiv sein k\u00f6nnte. Die Standardtherapie schlo\u00df ACE-Hemmer, Beta-Blocker, Diuretikum, Digitalis und Spironolacton ein in Dosierungen, die dem behandelnden Arzt \u00fcberlassen waren. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[130,316,309,312,314,313,315,317,320,311,307,319,310,308,306,3516,366],"class_list":["post-1491","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-captopril","tag-sartane","tag-valiant-studie","tag-valsartan"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1491"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1491\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}